Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats

Molina-Hernández, Miguel; Téllez-Alcántara, N. Patricia; Pérez-García, Julián; Olivera-López, Jorge I.; Jaramillo-Jaimes, M. Teresa

doi:10.1016/j.pnpbp.2008.06.010

Cited by 44 publications

(25 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NAC is a glutathione precursor that has been shown to be involved in oxidative homeostasis, dopamine modulations and to interact with several inflammatory markers [80]. Preclinical studies with these agents have yielded promising results so far, with evidence supporting an antidepressant-like effect in animal studies [81,82,83,84,85]. …”

Section: The Future Of Research On Inflammation In Mddmentioning

confidence: 99%

Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

Noto¹,

Rizzo²,

Mansur³

et al. 2014

Neuroimmunomodulation

View full text Add to dashboard Cite

In the last decades convergent findings from several lines of evidence has revealed a robust association between major depressive disorder (MDD) and inflammatory pathways. Despite this, the translation of these findings into new and better treatments for MDD has not occurred. The objective of this study is to comprehensively review what is already known with reasonable certainty on inflammatory pathways in MDD, to clarify some points that have been insufficiently studied and to discuss the implications of these findings for future studies targeting inflammatory pathways as a therapeutic tool for individuals with MDD.

show abstract

Section: The Future Of Research On Inflammation In Mddmentioning

confidence: 99%

Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

Noto¹,

Rizzo²,

Mansur³

et al. 2014

Neuroimmunomodulation

View full text Add to dashboard Cite

show abstract

“…In rodents, minocycline reduced immobility during the forced swim test,59 and co-administration of minocycline synergised the antidepressant-like actions of desipramine (but not fluoxetine) 60. Minocycline also abrogated the depression-like behaviour of rodents exposed to lipopolysaccharide (LPS) 61.…”

Section: Introductionmentioning

confidence: 99%

Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial

et al. 2012

View full text Add to dashboard Cite

IntroductionNew medication classes are needed to improve treatment effectiveness in the depressed phase of bipolar disorder (BD). Extant evidence suggests that BD is characterised by neural changes such as dendritic remodelling and glial and neuronal cell loss. These changes have been hypothesised to result from chronic inflammation. The principal aims of the proposed research is to evaluate the antidepressant efficacy in bipolar depression of minocycline, a drug with neuroprotective and immune-modulating properties, and of aspirin, at doses expected to selectively inhibit cyclooxygenase 1 (COX-1).Methods and analysis120 outpatients between 18 and 55 years of age, who meet DSM-IV-TR criteria for BD (type I or II) and for a current major depressive episode will be recruited to take part in a randomised, double-blind, placebo-controlled, parallel-group, proof-of-concept clinical trial following a 2×2 design. As adjuncts to existing treatment, subjects will be randomised to receive one of the four treatment combinations: placebo-minocycline plus placebo-aspirin, active-minocycline plus placebo-aspirin, placebo-minocycline plus active-aspirin or active-minocycline plus active-aspirin. The dose of minocycline and aspirin is 100 mg twice daily and 81 mg twice daily, respectively. Antidepressant response will be evaluated by assessing changes in the Montgomery–Asberg Depression Rating Scale scores between baseline and the end of the 6-week trial. As secondary outcome measures, the anti-inflammatory effects of minocycline and aspirin will be tested by measuring pre-treatment and post-treatment levels of C reactive protein and inflammatory cytokines.Ethics and disseminationMinocycline has been widely used as an antibiotic in doses up to 400 mg/day. Low-dose aspirin has been safely used on a worldwide scale for its role as an antithrombotic and thrombolytic. The study progress will be overseen by a Data, Safety and Monitoring Board, which will meet once every 6 months. Results of the study will be published in peer-reviewed publications.Trial registration numberClinical Trials.gov: NCT01429272.

show abstract

“…Both of them have antidepressant and anti-infl ammatory effects (Lai et al 2012 ;Loix et al 2011 ). Although initial studies seem promising, most of these agents are still in pre-clinical phase studies (Kulkarni et al 2009 ;Xu et al 2005 ;Molina-Hernandez et al 2008a ;Molina-Hernandez et al 2008b ;Smaga et al 2012 ).…”

Section: Antidepressant Effects Of Anti-infl Ammatory Agentsmentioning

confidence: 99%

Major Depression: An Immune-Inflammatory Disorder

Noto

Rizzo

Mansur

et al. 2015

Current Topics in Neurotoxicity

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a high prevalent mental disorder. Several lines of evidence have demonstrated that MDD is accompanied by cellmediated immune (CMI) activation and a chronic mild infl ammatory response, characterized by an increased production of pro-infl ammatory cytokines, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Immune-infl ammatory pathways are involved in the onset of depressive symptoms and partly explain the high comorbidity of MDD and general medical diseases. Moreover, antidepressants have anti-infl ammatory and negative immunoregulatory effects, while antiinfl ammatory agents may improve depressive symptoms. Despite the large evidence describing activated immune-infl ammatory responses in MDD, the pathophysiological mechanisms are unclear yet. Future studies should examine the clinical implications of those fi ndings by targeting immune-infl ammatory pathways as a therapeutic tool for individuals with MDD.

show abstract

Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats

Cited by 44 publications

References 51 publications

Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial

Major Depression: An Immune-Inflammatory Disorder

Contact Info

Product

Resources

About